ChromoGenics Balance Sheet Health
Financial Health criteria checks 4/6
ChromoGenics has a total shareholder equity of SEK42.8M and total debt of SEK66.8M, which brings its debt-to-equity ratio to 156.3%. Its total assets and total liabilities are SEK139.2M and SEK96.4M respectively.
Key information
156.3%
Debt to equity ratio
kr66.82m
Debt
| Interest coverage ratio | n/a |
| Cash | kr7.93m |
| Equity | kr42.76m |
| Total liabilities | kr96.41m |
| Total assets | kr139.16m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: CHRO's short term assets (SEK29.8M) exceed its short term liabilities (SEK27.4M).
Long Term Liabilities: CHRO's short term assets (SEK29.8M) do not cover its long term liabilities (SEK69.0M).
Debt to Equity History and Analysis
Debt Level: CHRO's net debt to equity ratio (137.7%) is considered high.
Reducing Debt: CHRO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CHRO has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CHRO is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.